Genentech changes support programs for ranibizumab access

April 1, 2008

South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis), including Lucentis Access Solutions and the Genentech Access to Care Foundation, in an effort to improve enrollment timing and broaden eligibility requirements.

South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis), including Lucentis Access Solutions and the Genentech Access to Care Foundation, in an effort to improve enrollment timing and broaden eligibility requirements.

The changes include:

  • Confirmation by phone-within 48 hours in most cases-that a patient who is uninsured or denied coverage is or may be eligible for free medication.

  • Conditional enrollment, via a letter faxed to the physician’s office, for eligible patients with inconclusive insurance coverage who otherwise qualify medically and financially.

  • Increased support to independent, non-profit, co-pay organizations, with a particular focus on groups that the company has determined have fast and efficient processes in place, such as the Chronic Disease Fund.

  • Expanded eligibility criteria for all of the company’s product access programs, including an increased annual adjusted gross income level (now $100,000, formerly $75,000) for patients who meet approved medical criteria as well as for patients who have reached their maximum lifetime insurance limits.

For more information, physicians and patients may contact 866/724-9394 or www.lucentisaccesssolutions.com.